“When this isn’t the right care for you, we’ll say so.”
Our commitment to your health supersedes everything. Elia is designed for specific midlife clinical needs. If your symptoms indicate a need for different, more urgent, or specialized care, we direct you to the right resources at no charge.
Immediate triage protocol.
The review is actively monitored for clinical red flags. If a critical symptom is identified during your review:
- stop_circleThe review is paused immediately so an inappropriate care plan isn’t recommended.
- infoYou receive clear, direct guidance on the next best step for your health.
- credit_card_offThere is no charge when the review is halted because of a clinical red flag.
Clinical boundaries by category.
Sleep support
When we refer out
- Symptoms suggesting Obstructive Sleep Apnea (OSA).
- Chronic insomnia requiring extensive CBT-I.
- Restless Leg Syndrome (RLS) indicators.
Pathway: primary care or a specialized sleep clinic.
Urinary tract
When we refer out
- Visible blood in urine (gross hematuria).
- Flank or back pain accompanied by high fever.
- More than 3 UTIs in a year without prior investigation.
Pathway: urgent care or prompt primary care evaluation.
Intimacy & comfort
When we refer out
- Unexplained pelvic pain independent of intercourse.
- Vaginal bleeding after menopause.
- Severe dermatological conditions of the vulva.
Pathway: in-person gynecologic examination.
Data security & privacy.
Your health information is sensitive, and its protection is a foundational requirement of our platform. Elia operates in alignment with HIPAA standards, with enterprise-grade encryption for data transmission and storage.
Audited access controls keep your review records, personal details, and care plans accessible only to you and your authorized clinical team. We do not, and will never, sell personal health information to third-party data brokers or advertisers.
Service areas.
Clinical reviews are currently available to residents of these states, in alignment with state medical-board regulations:
More states pending regulatory approval.